Chitotriosidase, Serum
Chitotriosidase is an enzyme that belongs to a human chitinase member of family 18 glycosyl hydrolases with the capability to hydrolyze chitin. The physiological functions of this enzyme are still unknown, but it is believed to play a defensive role against chitin-expressing pathogens, including fungi. It is exclusively secreted by activated human macrophages, so its activity has been proposed as a biochemical marker of macrophage accumulation.
Chitotriosidase is markedly elevated, often thousands-fold, in plasma of Gaucher disease patients. The enzyme is released from lipid-laden macrophages that accumulate in various tissues of Gaucher’s patients, thus the plasma level of chitotriosidase massively increases in Gaucher patients. Therefore, the measurement of chitotriosidase is widely used to aid the diagnosis of Gaucher disease. Plasma chitotriosidase activity at diagnosis reflects the extent of the body burden of Gaucher cells and could be an indirect measurement of severity of the disease. Furthermore, its level decreases markedly during enzyme replacement therapy (ERT) and rapidly increases when the treatment is interrupted, making it as a valuable biomarker in monitoring the effectiveness of treatment. Levels of chitotriosidase have been show to be modestly increased in other inherited lysosomal storage disorders, especially sphingolipidoses such as Niemann-Pick, GM1-gangliosidosis, and Krabbe disease. Since chitotriosidase is secreted by activated macrophage, the elevated plasma level can be observed in numbers of pathological conditions that involve the accumulation of macrophages, including sarcoidosis and atherosclerosis. It is also associated with fungal diseases as this enzyme may play a role in the degradation of chitin-containing pathogens.
- Differential diagnosis of Gaucher disease
- Monitoring effectiveness of enzyme replacement therapy (ERT) in Gaucher disease
- As an aid in diagnosis of other storage diseases such as Niemann-Pick disease, GM1-gangliosidosis, and Krabbe disease
Increased in:
- Gaucher disease
- Sarcoidosis
- Niemann-Pick disease
- GM1-gangliosidosis
- Krabbe disease
- Fabry disease
- β-thalassemia
- Atherosclerosis
- Leishmaniasis
- Plasmodium falciparum malaria
- Appendicitis
- Alzheimer disease
- Cerebral adrenoleukodystrophy
- Certain fungal infections
- Acute and chronic myeloid leukemia
- Rheumatoid arthritis
Decreased in:
- Associated with enzyme replacement therapy (ERT) in Gaucher disease
4-120 nmol/hr/mL
Fluorometric enzyme assay (4-methylumbelliferyl-beta-D-triacetylchitotrioside as substrate), Enzyme immunoassay.
Serum, Plasma, Tissue homogenate, other biological fluids.
Specimens should be frozen and analyzed within 4 days after collection.
- J Clin Invest. 1994;93:1288-1292. [PMID: 8132768]
- Clin Chem Lab Med. 2002;40:52-55. [PMID: 11924537]
- Clin Biochem. 2000;33:147-149. [PMID: 10751594]
- Clin Chim Acta. 2010;411:31-36. [PMID: 19808030]
- J Clin Immunol. 2013;33:264-270. [PMID: 22878841]
- Clin Biochem. 2013;46:1804-1807. [PMID: 24060732]
- Clin Chim Acta. 2004;344:101-107. [PMID: 15149877]
- J Inherit Metab Dis. 2006;29:647-652. [PMID: 16972172]
- Am J Hematol. 2002;71:7-10. [PMID: 12221666]
- Am J Emerg Med. 2012;30:775-777. [PMID: 21641156]